Innate Pharma (IPHA) Cash from Financing Activities (2020 - 2024)
Historic Cash from Financing Activities for Innate Pharma (IPHA) over the last 4 years, with Q4 2024 value amounting to -$6.4 million.
- Innate Pharma's Cash from Financing Activities fell 20350.91% to -$6.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$11.8 million, marking a year-over-year change of. This contributed to the annual value of -$6.5 million for FY2024, which is 20577.05% down from last year.
- Innate Pharma's Cash from Financing Activities amounted to -$6.4 million in Q4 2024, which was down 20350.91% from -$2.1 million recorded in Q4 2023.
- Innate Pharma's 5-year Cash from Financing Activities high stood at -$1.4 million for Q4 2020, and its period low was -$6.4 million during Q4 2024.
- Its 4-year average for Cash from Financing Activities is -$3.0 million, with a median of -$2.0 million in 2022.
- In the last 5 years, Innate Pharma's Cash from Financing Activities plummeted by 1342.01% in 2023 and then tumbled by 20350.91% in 2024.
- Quarter analysis of 4 years shows Innate Pharma's Cash from Financing Activities stood at -$1.4 million in 2020, then tumbled by 32.9% to -$1.9 million in 2022, then dropped by 13.42% to -$2.1 million in 2023, then plummeted by 203.51% to -$6.4 million in 2024.
- Its last three reported values are -$6.4 million in Q4 2024, -$2.1 million for Q4 2023, and -$1.9 million during Q4 2022.